June 14, 2022
An early-stage advisory and investment fund supporting emerging technologies in the biotech and pharmaceutical sector, today announced its participation in seed-round capital funding of Unravel Biosciences, Inc. ("Unravel"). The financial terms of the transaction were not disclosed.
Click to read the full articleJune 14, 2022
Scilex Holding Company has entered into a license and commercialization agreement with ROMEG Therapeutics for the exclusive right to market and distribute Gloperba, an oral solution for adults suffering from gout, in the US
Click to read the full articleJuly 5, 2022
Unravel Biosciences today announced a partnership with TMA Precision Health aimed at identifying rare Rett Syndrome patients for inclusion in Unravel's first-in-human reformulated drug trial.
Click to read the full articleApril 29, 2025
Submissions follow Ethics Committee Approvals for Both Studies Received Earlier This Month and Have Been Accepted for INVIMA Priority Review Under Fast Track Program for Rare Disease
Click to read the full articleFebruary 27, 2025
The agreement represents one of the largest biopharma-patient community partnerships of its kind and will accelerate the identification of potential drug candidates across multiple ultra-rare diseases.
Click to read the full articleJanuary 16, 2025
PALO ALTO, Calif., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company
Click to read the full articleOctober 24, 2024
Study site selection and finalization of clinical trial agreement final step toward initiation of RVL-001 proof-of-concept clinical studies early next year
Click to read the full articleAugust 29, 2024
PALO ALTO, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring
Click to read the full articleJune 6, 2024
PALO ALTO, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating
Click to read the full articleMay 28, 2024
Initiation of global clinical development program for RVL-001 in Rett syndrome underway, with recently announced Rett studies in the US led by Vanderbilt and in Colombia led by Unravel.
Click to read the full articleMarch 20, 2024
Seek approval from the FDA for the modification of the Gloperba® label to include its ability to utilize dosing flexibility of liquid formulation
Click to read the full articleNovember 27, 2023
ALO ALTO, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”)
Click to read the full articleMay 15, 2023
FDA pre-IND feedback provides a clear path forward to initiate proof-of-concept clinical study in Rett Syndrome patients later this year
Click to read the full articleJanuary 31, 2023
Membership with MassBio expected to enhance RTK Group's mission to support advancing the development of promising technology to improve patient lives.
Click to read the full articleRTK is a biopharmaceutical advisory and investment fund that supports companies
by enabling them to develop promising technologies and reach their potential to benefit patients.
We have one goal: to enable better patient lives and a better world through better healthcare. We take great satisfaction in partnering with companies having high potential to disrupt the healthcare ecosystem and helping support high‐performing management teams to realize their goals.